18Nov 2018

DIAGNOSTIC AND PROGNOSTIC UTILITY OF NRAS MUTATION GENE TESTING IN CYTOLOGICALLY INDETERMINATE THYROID NODULES.

Crossref Cited-by Linking logo

Plum Print visual indicator of research metrics
  • Captures
    • Readers: 2
see details

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Objective: to evaluate the diagnostic and prognostic impact of NRAS mutational gene testing in fine needle aspiration samples from cytologically indeterminate thyroid nodules. Background: Fine needle aspiration cytology (F.N.A.C) is the cornererstone of assessment of thyroid nodules, but 15 to 30% of aspirates are indeterminate and are mostly referred for diagnostic surgery; exposing patients to postoperative undue effects. This raises the need to improve preoperative diagnosis of such nodules and here's the role of molecular markers (like RAS) detection in aspirates from these nodules as an adjunct to F.N.A.C. Patients and Methods: In this study 100 patients with cytologically indeterminate thyroid nodules were subjected to NRAS gene mutation testing at exons 12/13 & 61 by direct sequencing. 90 cases were managed surgically, while 10 cases were followed up by ultrasound (U.S) after 1 year. Results: The incidence of NRAS mutation was 34%, of which NRAS exon 61 mutations were the commonest (76.4%). In surgery correlation group, 19.6% of the benign cases were +ve for NRAS mutation (all were F.As), while of the malignant cases, 61.5% were +ve for NRAS mutation. The probability of cancer in NRAS +ve cases was 70.6%. The PPV, NPV, sensitivity and specificity for NRAS mutation testing was 70.6%, 73.2%, 61.5% and 80.4% respectively. The accuracy of NRAS mutation testing was 72.2%. Conclusion: NRAS gene mutational testing represents a promising diagnostic tool for patients with cytologically indeterminate thyroid nodules especially those with follicular patterned thyroid lesions (F.A, F.V.P.T.C &F.T.C) and can be used as a tumor marker in such patients.

  1. Gharib H.,?Papini E.,?Paschke R.,?Duick D. S.,?Valcavi R.,?Heged?s L., et al. American Association of Clinical endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract. 2010; 16:468?475.
  2. Wang C. C.,?Friedman L.,?Kennedy G. C.,?Wang H.,?Kebebew E.,?Steward D. L., et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011; 21:243-51.
  3. Cibas E. S. & Syed A. Z. The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol. 2009; 132:658-65.
  4. Shrime M. G.,?Goldstein D. P.,?Seaberg R. M.,?Sawka A. M.,?Rotstein L.,?Freeman J. L., et al. Cost effective management of low-risk papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007; 133:1245-53.
  5. Ferraz C., Eszlinger M. & Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011; 96:2016-26.
  6. Nikiforov Y. E.,?Ohori N. P.,?Hodak S. P.,?Carty S.E.,?LeBeau S. O.,?Ferris R. L., et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96:3390-7.
  7. Kyriakis J. M. Thinking outside the box about Ras. J Biol Chem. 2009; 284:10993?10994.
  8. Howell G. M.,?Hodak S. P. &?Yip L.RAS?mutations?in?thyroid cancer. 2013; 18(8):926-32.
  9. Nikiforov Y. E., Steward D. L., Robinson-Smith T. M., Haugen B. R., Klopper J. P., Zhu Z., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94: 2092?2098.
  10. An J. H.,?Song K. H.,?Kim S. K.,?Park K. S.,?Yoo Y. B.,?Yang J. H., et al. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2015 May; 82(5):760-6.
  11. Schulten H. J., Salama S., Al-Ahmadi A., Al-Mansouri Z., Mirza Z., Al-Ghamdi K., et al. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. ANTICANCER RESEARCH 33.2013: 4779-4784.
  12. Park J. Y., Kim W. Y., Hwang T. S., Lee S. S., Kim H., Han H. S., et al.? ?BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma,? Endocrine Pathology. ?2013; vol. 24, no.2, pp. 69?76.
  13. Rivera M., Ricarte-Filho J., Knauf J., Shaha A., Tuttle M., Fagin J. A., et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs. infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010; 23: 1191-1200.
  14. Fukahori M., Yoshida A., Hayashi H., Yoshihara M., Matsukuma S., Sakuma Y., et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: New insights from a single center and a large patient cohort. Thyroid. 2012; 22: 683-689.
  15. Garcia-Rostan G.,?Zhao H.,?Camp R. L.,?Pollan M.,?Herrero A.,?Pardo J., et al. Ras Mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21:3226 ?3235.
  16. Bae J. S., Choi S. K., Jeon S., Kim Y., Lee S., Lee Y. S., et al. Impact of NRAS mutations on the diagnosis of follicular neoplasm of the thyroid. Int J Endocrinol. 2014; 2014: 289834.
  17. Fakhruddin N.,?Jabbour M.,?Novy M.,?Tamim H.,?Bahmad H.,?Farhat F.,?et al. BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases. Sci Rep. 2017 Jul 5; 7(1):4666.
  18. Clinkscales W.,?Ong A.,?Nguyen S.,?Harruff E. E.&?Gillespie M. B. Diagnostic value of RAS mutations in indeterminate thyroid nodules. Otolaryngol head neck surg. 2017 Mar; 156(3):472-479.

[Yasser Ali Elsayed, Atif Mohamed Abd El-Latif, Mohamed Hossam Eldeen Zaghloul, Ahmed Elsayed lofty and Mohamed Mostafa Mahmoud. (2018); DIAGNOSTIC AND PROGNOSTIC UTILITY OF NRAS MUTATION GENE TESTING IN CYTOLOGICALLY INDETERMINATE THYROID NODULES. Int. J. of Adv. Res. 6 (Nov). 744-753] (ISSN 2320-5407). www.journalijar.com

Mohamed Mostafa Mahmoud
assistant lecturer of general surgery,Faculty of medicine,Mansoura university

DOI:

Article DOI: 10.21474/IJAR01/8055      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8055

Download Full Paper

Download PDF No. of Downloads: 27 | No. of Views: 85